A recent study in stage I lung carcinoma has unveiled the role that PDPN+ CAFs have in attenuating anti-tumor immunity by decreasing the CD8/Foxp3 T cell ration, supporting monocyte recruitment and their differentiation into TAMs [112]. This evidence concerns the gene FOXP3 and neoplasm.